These compounds may interact with:
Nuclear receptor subfamily 4 group A member 1
Potentially involved in: carcinoma; cancer; fetal adenoma; vascular disease; staphyloenterotoxemia; endometriosis; insulin resistance; kidney diseases; proteinuria; myocardial ischemia; adrenocortical carcinoma; atypical teratoid/rhabdoid tumor; bipolar disorder; breast cancer; chronic rhinosinusitis; cystic fibrosis; duchenne muscular dystrophy; gastric cancer; group 4 medulloblastoma; hepatocellular carcinoma
Disease data sourced from Pharos.